Lampl C et al. – In neither migraine nor episodic tension–type headache (ETTH) does pre–treatment headache intensity predict success or failure of aspirin. This is not an arguable basis for stratified care in migraine. In both disorders, aspirin is first–line treatment regardless of headache intensity.

• With regard to the first assumption, authors developed a rhetorical argument that need for treatment is underpinned by expectation of benefit, not by illness severity.
• To address the second, authors reviewed individual patient data from 6 clinical trials of aspirin 1000 mg in migraine (N = 2079; 1165 moderate headache, 914 severe) and one of aspirin 500 and 1000 mg in ETTH (N = 325; 180 moderate, 145 severe), relating outcome to pre–treatment headache intensity.

• In migraine, for headache relief at 2 hours, a small (4.7%) and non–significant risk difference (RD) in therapeutic gain favored moderate pain; for pain freedom at ...read more

Daviglus ML et al. – Currently, insufficient evidence exists to draw firm conclusions on the association of any modifiable factors with risk of Alzheimer disease(AD).

• Study inclusion criteria for the evidence report were participants aged 50 years and older from general populations in developed countries.
• Minimum sample sizes of 300 for cohort studies and 50 for randomized controlled trials.
• At least 2 years between exposure and outcome assessment; and use of well–accepted diagnostic criteria for AD.
• Included studies were evaluated for eligibility and data were ed.
• Quality of overall evidence for each factor was summarized as low, moderate, or high.

French JA et al. – This study demonstrates that EZG(RTG) is effective as add-on therapy for reducing seizure frequency in patients with drug-resistant partial-onset seizures.

• RESTORE 1 was a multicenter, randomized, double-blind, parallel-group trial.
• Following a prospective 8-week baseline phase, patients entered an 18-week double-blind treatment period (6-week forced dose titration to EZG[RTG] 1,200 mg/day in 3 equally divided doses or placebo, followed by a 12-week maintenance phase).
• Results were analyzed on an intent-to-treat basis for the entire 18-week period and for patients reaching the maintenance phase.

Womack KB et al. – Temporoparietal hypometabolism in Frontotemporal Lobar Degeneration(FTLD) is common and may cause inaccurate interpretation of positron emission tomographic scans with fludeoxyglucose F 18 scans. An interpretation paradigm that focuses on the absence of hypometabolism in ...read more

Read all Neurology News Articles at MDLinx.com

Larsson SC et al. – The association between coffee consumption and cerebral infarction was not modified by smoking status, body mass index, history of diabetes or hypertension, or alcohol consumption. These findings suggest that low or no coffee consumption is associated with ...read more

Read all Neurology News Articles at MDLinx.com

Quinn TJ et al. – Substantial literature describing BI clinimetrics in stroke is available; however, questions remain regarding certain properties. The "BI" label is used for a number of instruments and the authors urge greater consistency in methods, content, and scoring.

Huang YH et al. – Lower mean GCS on admission is independently predictive of seizures, most of which occur within the first three months after chronic subdural hematoma.  Read More

Read all Neurology News articles at MDLinx.com

Glasser SP et al. – The prevalence of Prehypertension increased by age and African–American race. In addition, a higher prevalence of Prehypertension was observed with elevated high–sensitivity C reactive protein, diabetes, microalbuminuria, and those with heavy alcohol consumption compared to those without these factors.

Uitdehaag B et al. – The findings of these post hoc analyses suggest that high exposure to sc interferon beta–1a may be associated with better clinical outcomes than low exposure, and also highlight the importance of maximizing adherence. Additional prospective investigation is warranted to evaluate further the effects of treatment exposure on outcomes and to determine the benefits of interventions to improve adherence.